Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Mar;9(3):296-311.
doi: 10.1002/acn3.51516. Epub 2022 Feb 24.

Lipid levels and the risk of dementia: A dose-response meta-analysis of prospective cohort studies

Ying Zhu  1 , Xu Liu  1 , Ruixia Zhu  1 , Jingjing Zhao  1 , Qianwen Wang  1
Affiliations
Meta-Analysis

Lipid levels and the risk of dementia: A dose-response meta-analysis of prospective cohort studies

Ying Zhu et al. Ann Clin Transl Neurol. 2022 Mar.

Abstract

Objectives: We performed a dose-response meta-analysis to estimate the association between lipid profiles with the risk of dementia and the potential differences according to the subtype of dementia based on prospective studies.

Methods: We searched PubMed, Embase and Web of Science for relevant articles and performed a meta-analysis. We applied fixed or random-effects models to calculate pooled relative risk (RR) with their 95% confidence intervals (CI). The dose-response relationship was assessed by restricted cubic spline.

Results: Twenty-five prospective studies comprising 362,443 participants and 20,121 cases were included in the final analysis. We found that increased risk of all-cause dementia could be predicted by elevated total cholesterol (TC) (RR = 1.13, 95% CI 1.04-1.22). When looking at dementia subtypes, we also observed high TC and triglycerides (TG) may increase the future risk of Alzheimer's disease (AD), with a pooled RR of 1.13 (95% CI: 1.06-1.21) and 1.10 (95% CI: 1.04-1.15) respectively. Moreover, a dose-response analysis revealed a linear association between TC or TG and the risk of AD, with a pooled RR of 1.09 (95% CI: 1.02-1.16) and 1.12 (95% CI: 1.05-1.21) for per 3-mmol/L increment in TC and TG, respectively.

Conclusions: Current evidence suggest that every 3-mmol/L increase in blood TC or TG is linearly associated with a 9% or 12% increase in RR of AD, supporting the notion that high TC and TG levels appear to play a causal role in the development of AD.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of study selection in our meta‐analysis.
Figure 2
Figure 2
Overall pooled analysis of association between TC levels and all‐cause dementia. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 3
Figure 3
Sensitivity analyses excluding each study subsequently from the analysis for the association between blood TC concentration and relative risk of all‐cause dementia. The vertical lines indicate summary estimate (1.13) and 95% confidence interval (1.04–1.22) from meta‐analysis of all studies.
Figure 4
Figure 4
Overall pooled analysis of association between TC levels and Alzheimer‐type dementia. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 5
Figure 5
Sensitivity analyses excluding each study subsequently from the analysis for the association between blood TC concentration and relative risk of Alzheimer‐type dementia. The vertical lines indicate summary estimate (1.13) and 95% confidence interval (1.06–1.21) from meta‐analysis of all studies.
Figure 6
Figure 6
Dose–response relationship between TC and risk of Alzheimer's disease.
Figure 7
Figure 7
Overall pooled analysis of association between TG levels and Alzheimer‐type dementia. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 8
Figure 8
Sensitivity analyses excluding each study subsequently from the analysis for the association between blood TG concentration and relative risk of Alzheimer‐type dementia. The vertical lines indicate summary estimate (1.10) and 95% confidence interval (1.04–1.15) from meta‐analysis of all studies.
Figure 9
Figure 9
Dose–response relationship between TG and risk of Alzheimer's disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and meta‐analysis. Alzheimers Dement. 2013;9:63‐75.e2. doi:10.1016/j.jalz.2012.11.007 - DOI - PubMed
    1. Grande G, Qiu C, Fratiglioni L. Prevention of dementia in an ageing world: evidence and biological rationale. Ageing Res Rev. 2020;64:101045. doi:10.1016/j.arr.2020.101045 - DOI - PubMed
    1. Burns M, Duff K. Cholesterol in Alzheimer's disease and tauopathy. Ann N Y Acad Sci. 2002;977:367‐375. - PubMed
    1. Sparks DL, Liu H, Scheff SW, Coyne CM, Hunsaker JC III. Temporal sequence of plaque formation in the cerebral cortex of non‐demented individuals. J Neuropathol Exp Neurol. 1993;52(2):135‐142. - PubMed
    1. Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease? J Neurosci Res. 2003;72:141‐146. - PubMed

Publication types